These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19166896)

  • 1. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perospirone in the treatment of patients with delirium.
    Takeuchi T; Furuta K; Hirasawa T; Masaki H; Yukizane T; Atsuta H; Nishikawa T
    Psychiatry Clin Neurosci; 2007 Feb; 61(1):67-70. PubMed ID: 17239041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
    Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole in treatment-resistant depression: an extended follow-up.
    Cassano P; Lattanzi L; Soldani F; Navari S; Battistini G; Gemignani A; Cassano GB
    Depress Anxiety; 2004; 20(3):131-8. PubMed ID: 15549689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perospirone in the treatment of schizophrenia: effect on verbal memory organization.
    Araki T; Yamasue H; Sumiyoshi T; Kuwabara H; Suga M; Iwanami A; Kato N; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):204-8. PubMed ID: 16300872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, flexible-dose study of memantine in major depressive disorder.
    Ferguson JM; Shingleton RN
    Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS; Ng F; Berk M
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.
    Papakostas GI
    Essent Psychopharmacol; 2005; 6(4):209-20. PubMed ID: 16041917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism.
    Kusumi I; Masui T; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):520-2. PubMed ID: 18006133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study.
    Siwek M; Dudek D; Paul IA; Sowa-Kućma M; Zieba A; Popik P; Pilc A; Nowak G
    J Affect Disord; 2009 Nov; 118(1-3):187-95. PubMed ID: 19278731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92).
    Rasmussen NA; Schrøder P; Olsen LR; Brødsgaard M; Undén M; Bech P
    Nord J Psychiatry; 2005; 59(3):173-8. PubMed ID: 16208839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation.
    Licht RW; Qvitzau S
    Psychopharmacology (Berl); 2002 May; 161(2):143-51. PubMed ID: 11981594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.